European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness
- PMID: 38719772
- DOI: 10.1183/13993003.00335-2024
European Respiratory Society clinical practice guideline on symptom management for adults with serious respiratory illness
Abstract
Respiratory symptoms are ubiquitous and impair health-related quality of life in people with respiratory disease. This European Respiratory Society (ERS) task force aimed to provide recommendations for symptomatic treatment in people with serious respiratory illness. The ERS task force comprised 16 members, including representatives of people with serious respiratory illness and informal caregivers. Seven questions were formulated, six in the PICO (Population, Intervention, Comparison, Outcome) format, which were addressed with full systematic reviews and evidence assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation). One question was addressed narratively. An "evidence-to-decision" framework was used to formulate recommendations. To treat symptoms in people with serious respiratory illness, the task force suggests the use of graded exercise therapy (conditional recommendation, low certainty of evidence); and suggests the use of a multicomponent services, handheld fan and breathing techniques (conditional recommendations, very low certainty of evidence). The task force suggests not to use opioids (conditional recommendation, very low certainty of evidence); and suggests either administering or not administering supplemental oxygen therapy (conditional recommendation, low certainty of evidence). The task force suggests that needs assessment tools may be used as part of a comprehensive needs assessment, but do not replace patient-centred care and shared decision making (conditional recommendation, low certainty of evidence). The low certainty of evidence, modest impact of interventions on patient-centred outcomes, and absence of effective strategies to ameliorate cough highlight the need for new approaches to reduce symptoms and enhance wellbeing for individuals who live with serious respiratory illness.
Copyright ©The authors 2024. For reproduction rights and permissions contact permissions@ersnet.org.
Conflict of interest statement
Conflict of interest: A.E. Holland reports non-financial support from BOC Australia and Air Liquide Australia for oxygen therapy clinical trials, outside the submitted work. K. Marsaa reports lectures fees from GlaxoSmithKline, AstraZeneca, Novartis and Boehringer Ingelheim, outside the submitted work. A-M. Russell declares speaker fees and support for the development of a podcast series from Boehringer Ingelheim, and speaker fees from Hoffman La Roche, outside the submitted work. R. Saggu reports, within the past 2 years, speaker fees from GSK and TEVA, support for conference attendance and advisory board participation from GSK, Sanofi, AZ and TEVA, and has carried out clinical educator commissioned work for RCGP and RPS. J. Solheim declares membership of the Pulmonary Fibrosis Early Research Steering Committee, Boehringer Ingelheim. M. Wijsenbeek reports grants (paid to institution) from The Dutch Pulmonary Fibrosis Patients Association, The Dutch Lung Foundation, The Netherlands Organisation for Health Research and Development, The Thorax Foundation, Sarcoidosis.nl, AstraZeneca/Daiichi-Sankyo, Boehringer Ingelheim (BI) and Hoffmann-La Roche, and consulting or speaker fees (paid to institution) from AstraZeneca, BI, Bristol Myers Squibb, CSL Behring, Galapagos, Galecto, Hoffmann-La Roche, Horizon, Kinevant Sciences, Molecure, NeRRe, Novartis, PureTech, Thyron, Trevi and Vicore. T. Tonia declares acting as ERS methodologist. The remaining authors have no potential conflicts of interest to disclose.
Comment in
-
ERS guideline recommendation on airflow for breathlessness: the pitfalls of applying GRADE evidence ratings to complex non-pharmacological interventions.Eur Respir J. 2025 Feb 6;65(2):2402244. doi: 10.1183/13993003.02244-2024. Print 2025 Feb. Eur Respir J. 2025. PMID: 39915045 No abstract available.
-
Reply: A recommendation for increased airflow to relieve breathlessness: evidence in context is a strength of the GRADE approach.Eur Respir J. 2025 Feb 6;65(2):2402463. doi: 10.1183/13993003.02463-2024. Print 2025 Feb. Eur Respir J. 2025. PMID: 39915046 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources